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Osteocytes are abundant cells in bone, which contribute to bone maintenance. Osteocytes express receptor activator of nuclear
factor kappa-B ligand (RANKL) and regulate osteoclast formation. Orthodontic tooth movement (OTM) occurs by osteoclast
resorption of alveolar bone. Osteocyte-derived RANKL is critical in bone resorption during OTM. Additionally, tumor necrosis
factor-α (TNF-α) is important in osteoclastogenesis during OTM. Sclerostin has been reported to enhance RANKL expression
in the MLO-Y4 osteocyte-like cell line. This study investigated the effect of TNF-α on sclerostin expression in osteocytes during
OTM. In vitro analysis of primary osteocytes, which were isolated from DMP1-Topaz mice by sorting the Topaz variant of
GFP-positive cells, revealed that SOST mRNA expression was increased when osteocytes were cultured with TNF-α and that
RANKL mRNA expression was increased when osteocytes were cultured with sclerostin. Moreover, the number of TRAP-
positive cells was increased in osteocytes and osteoclast precursors cocultured with sclerostin. In vivo analysis of mouse calvariae
that had been subcutaneously injected with phosphate-buffered saline (PBS) or TNF-α revealed that the number of TRAP-
positive cells and the percentage of sclerostin-positive osteocytes were higher in the TNF-α group than in the PBS group.
Furthermore, the level of SOST mRNA was increased by TNF-α. As an OTM model, a Ni-Ti closed-coil spring connecting the
upper incisors and upper-left first molar was placed to move the first molar to the mesial direction in wild-type (WT) mice and
TNF receptor 1- and 2-deficient (TNFRsKO) mice. After 6 days of OTM, the percentage of sclerostin-positive osteocytes on the
compression side of the first molar in TNFRsKO mice was lower than that in WT mice. In this study, TNF-α increased
sclerostin expression in osteocytes, and sclerostin enhanced RANKL expression in osteocytes. Thus, TNF-α may play an
important role in sclerostin expression in osteocytes and enhance osteoclast formation during OTM.
1. Introduction
Osteocytes, derived from osteoblasts, comprise 90%–95% of
cells within bone tissue; they are stellate shaped and construct
an intercellular network [1]. Multiple studies have shown
that osteocytes play a central role as mechanosensory cells
within bone [2, 3]; notably, osteocytes regulate bone remod-
eling by sensing mechanical stimulation and expression of
various genes and proteins [4, 5].
Osteoclasts are large multinucleated cells derived from
hematopoietic stem cells, which are responsible for bone
resorption. Receptor activator of nuclear factor kappa-B
ligand (RANKL) and macrophage colony stimulating factor
(M-CSF) are known as essential factors for osteoclastogenesis
[6]. Tumor necrosis factor-α (TNF-α) also affects osteoclas-
togenesis and can induce differentiation of osteoclast precur-
sors into osteoclasts both in vitro [7–9] and in vivo [10, 11].
TNF-α is reportedly detected in response to excessive ortho-
dontic force in rat periodontal tissues [12]. Moreover, TNF-α
has been shown to play an important role in osteoclastogen-
esis during orthodontic tooth movement (OTM) [13–15].
Recently, two research groups found that osteocytes
express RANKL and have a major role in osteoclastogenesis
[16, 17]. Therefore, they have been proposed as a new
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therapeutic target for the treatment of osteoporosis [18–20].
In OTM, osteoclastic bone resorption occurs on the com-
pression side, whereas osteoblastic bone formation occurs
on the tension side [21]. In a study of OTM in transgenic
mice, osteocytes were ablated by injecting diphtheria toxin
into transgenic mice expressing diphtheria toxin receptors
on the surface of osteocytes; subsequently, both the tooth
movement distance and the number of osteoclasts in the
compression side significantly decreased [22]. Recent investi-
gations have demonstrated that osteocyte RANKL expression
plays a key role in alveolar bone remodeling during OTM,
using mice that specifically lack RANKL in osteocytes [23].
Sclerostin, which is encoded by the SOST gene, is a
secreted glycoprotein that is primarily expressed in osteo-
cytes; notably, it is an important negative regulator of bone
homeostasis through inhibition of bone formation by osteo-
blasts [24]. Sclerostin binds to LRP5/6 as an antagonist of
canonical Wnt signaling, thereby leading to inhibition of
bone formation [25]. Sclerostin has been reported to increase
RANKL expression in the MLO-Y4 osteocyte-like cell line,
thereby promoting osteoclast formation [26]. TNF-α has
been shown to upregulate sclerostin expression in MLO-
Y4 cells [27]; consistent with this finding, the use of a
TNF-α antagonist was able to diminish RANKL and scler-
ostin expression in the osteocytes of diabetic rats with peri-
odontitis [28]. In general, mechanical stimulation to the
bone is thought to reduce sclerostin expression in osteocytes
[29]. However, some studies have shown that sclerostin
expression can be increased by mechanical stimulation in
mouse models of OTM [30–32]. The interaction between
mechanical stimulation and sclerostin expression in osteo-
cytes remains unclear. In addition, there has been no report
regarding the effect of TNF-α on the expression of sclerostin
in primary osteocytes.
In the present study, we investigated the influence of
TNF-α on the expression of sclerostin in primary osteocytes,
then examined how TNF-α affects the expression of scleros-
tin in osteocytes during OTM.
2. Materials and Methods
2.1. Mice and Reagents. C57BL/6J (wild-type: WT) mice were
purchased from CLEA Japan Inc. (Tokyo, Japan). B6;129S-
Tnfrsf1atm1Imx (p55, TNFR1-deficient) Tnfrsf1btm1Imx/J
(p75, TNFR2-deficient) (TNFRsKO) mice and C57BL/6-
Tg(Dmp1-Topaz)1lkal/J mice were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). The protocols
for all animal procedures were performed in accordance with
Tohoku University regulations.
Recombinant mouse TNF-α for in vivo experiments was
prepared in our laboratory as previously described [10].
Recombinant mouse TNF-α and recombinant human scler-
ostin (rhSCL) for in vitro experiments were purchased from
R&D Systems (Minneapolis, MN, USA).
2.2. Preparation of Osteocytes. We followed a previously
described method for osteocyte isolation, with minor modifi-
cations [33]. Calvariae of 5–6-day-old Dmp1-Topaz mice
were dissected. A 0.2% (w/v) collagenase (Wako, Japan) solu-
tion was prepared immediately before use in isolation buffer
(70mM NaCl, 10mM NaHCO3, 60mM sorbitol, 3mM
K2HPO4, 1mM CaCl2, 0.1% (w/v) bovine serum albumin
(BSA), 0.5% (w/v) glucose, and 25mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES)). A 5mM ethyl-
enediaminetetraacetic acid (EDTA; Wako) solution was pre-
pared with 0.1% BSA in phosphate-buffered saline (PBS) and
sterilized by filtration through a 0.2 μm filter. Calvariae were
incubated in collagenase solution for 20min or in EDTA
solution for 15min at 37°C with agitation, and the digests
were collected. Incubations were performed as follows:
collagenase (fraction 1), EDTA (fraction 2), collagenase
(fraction 3), collagenase (fraction 4), and EDTA (fraction
5). Cell fractions 2–5 were cultured overnight, and adherent
cells were collected with a trypsin-EDTA solution (Sigma-
Aldrich, Japan). The cell suspension was then filtered
through a 40 μm nylon cell strainer (Falcon, USA). Topaz-
positive osteocytes were isolated from cell fractions 2–5 by
using a cell sorter (FACSAria II). Cell fraction 2 was used,
as it comprised the osteoblast-rich fraction. Cells were
cultured in alpha minimum essential medium (α-MEM)
(Wako, Japan) containing 10% fetal bovine serum (FBS)
and 1% penicillin-streptomycin (PS; 100 IU/mL penicillin G
and 100 μg/mL streptomycin).
2.3. Preparation of Osteoclast Precursors. C57BL/6J mice were
sacrificed; then, femora and tibiae were immediately dis-
sected. The epiphyses of these bones were cut, and the bone
marrow was then flushed out with α-MEM (Wako, Japan).
The cell suspension was filtered through a 40 μm nylon cell
strainer (Falcon). The obtained cells were cultured in α-
MEM containing 10% FBS, 1% PS, and M-CSF for 3 days.
Adherent cells were collected with a trypsin-EDTA solution
(Sigma-Aldrich) and used as osteoclast precursors [34].
2.4. Preparation of RNA and Real-Time Reverse Transcription
Polymerase Chain Reaction (RT-PCR) Analysis. For in vitro
analysis, osteocytes were incubated in 24-well plates in cul-
ture medium that was supplemented with TNF-α (0 ng/mL
and 100ng/mL) for 1 day or 3 days, and with rhSCL
(0 ng/mL, 1 ng/mL, 10 ng/mL, and 100 ng/mL) for 2 days.
Total RNA from osteocytes was isolated with an RNeasy
Mini Kit (Qiagen, USA).
For in vivo analysis, PBS or TNF-α (3.0 μg/day) was
injected into the supracalvarial region of C57BL/6J mice,
once daily for 5 days. After 5 days, the mice were sacri-
ficed and calvariae were immediately removed and frozen
in liquid nitrogen. Subsequently, calvariae were homoge-
nized using a Micro Smash MS-100R (TOMY SEIKO
Co. Ltd., Japan) and then centrifuged in TRIzol Reagent
(Invitrogen, USA). Total RNA was extracted from samples
with an RNeasy Mini Kit (Qiagen), in accordance with the
manufacturer’s protocol.
cDNA was synthesized by using SuperScript IV
Reverse Transcriptase (Invitrogen). Gene expression levels
were analyzed by real-time RT-PCR in a Thermal Cycler
Dice Real Time System (Takara, Japan) using TB Green
Premix Ex Taq II (Takara, Japan). The PCR cycling condi-
tions were as follows: initial denaturation stage (95°C for
2 Journal of Immunology Research
30 sec), amplification stage (50 amplification cycles with each
cycle composed of a denaturation step of 95°C for 5 s and an
annealing step of 60°C for 30 s), and final dissociation stage (a
cycle composed of 95°C for 15 s, 60°C for 30 s, and 95°C for
15 s). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA was used to normalize each gene expression levels.
The primers were as follows: GAPDH, 5′-GGTGGAGCC
AAAAGGGTCA-3′ and 5′-GGGGGCTAAGCAGTTGGT-




ATTT-3′ and 5′-CTTGGCCCAGCCTCGAT-3′; and OPG,
5′-ATCAGAGCCTCATCACCTT-3′ and 5′-CTTAGGTC
CAACTACAGAGGAAC-3′.
2.5. Coculture of Osteocytes and Osteoclast Precursors for
Osteoclast Formation. Osteocytes (2 × 104 cells) and osteo-
clast precursors (5 × 104 cells) were cocultured in 200 μL α-
MEM containing 10% FBS and 1% PS in a 96-well plate, in
the presence of 10-8M 1,25-dihydroxyvitamin D3 (Sigma-
Aldrich) and 10-6M prostaglandin E2 (Sigma-Aldrich) with
and without rhSCL (100 ng/mL). Medium was changed on
the second day.
After 5 days, cell cultures were fixed in a 4% parafor-
maldehyde solution for 30min, then permeabilized with
0.2% Triton X-100 for 1 h at room temperature. Tartrate-
resistant acid phosphatase (TRAP) staining solution was
prepared to visualize osteoclasts by mixing acetate buffer
(pH5.0), naphthol AS-MX phosphate (Sigma-Aldrich), Fast
Red Violet LB Salt (Sigma-Aldrich), and 50mM sodium
tartrate. TRAP-positive cells with three or more nuclei were
regarded as osteoclasts and were counted under a light
microscope [34].
2.6. Experimental Tooth Movement. OTM was performed as
described previously [35]. In brief, 8–12-week-old male WT
mice and TNFRsKOmice were anesthetized and a nickel tita-
nium (Ni-Ti) closed-coil spring (TOMY SEIKO Co. Ltd.)
was attached between the upper incisor and left first molar.
The appliance was fixed with a stainless-steel wire (0.01mm
diameter) to the hole drilled in the upper anterior alveolar
bone, then tied to the first molar. The first molar was moved
in the mesial direction with a force of 10 g.
2.7. Preparation for Histological Observation. Harvested
calvariae and maxillae were fixed overnight in 4% parafor-
maldehyde at 4°C. Samples were decalcified in 14% EDTA
for 3 days (calvariae) or 1 month (maxillae) at 4°C. After
dehydration, samples were embedded in paraffin and cut
in coronal sections of 5 μm (calvariae) and horizontal sec-
tions of 4μm (maxillae) thickness. Maxillae sections were
taken at approximately 150μm from the root branch of
the upper-left first molar.
To confirm osteoclast formation, calvariae paraffin sec-
tions were stained with TRAP solution, then counterstained
with hematoxylin. TRAP-positive cells with three or more
nuclei were regarded as osteoclasts. The numbers of TRAP-
positive cells were counted and averaged within the suture
of sagittal sutures [34].
For immunohistochemistry, paraffin sections were
deparaffinized, rehydrated, and then treated with 3% H2O2
for 15min. Thereafter, sections were blocked with 5% skim
milk for 30min at 37°C and treated with anti-SOST poly-
clonal goat antibody AF1589 (1 : 50 diluted in blocking
buffer; R&D Systems) overnight at 4°C. After sections had
been rinsed, they were processed with VECTASTAIN Elite
ABC Kit PK-6105 (Vector Laboratories Inc., USA) and
treated with 3,3′-diaminobenzidine (DAB). Hematoxylin
was used for counterstaining [36]. We confirmed that the
percentage of sclerostin-positive osteocytes was within the
range of 400 μm× 200 μm from the mesial periodontal liga-
ment on the compression side of the distobuccal root of the
upper-left first molar.
2.8. Statistical Analysis. All values are presented as mean ±
standard deviation. Statistical analyses were performed using
Student’s t-test. P < 0 05 was considered to be statistically
significant.
3. Results
3.1. Isolation and Characterization of Osteocytes. To isolate
high-purity osteocytes, we sorted Topaz-positive and nega-
tive cells from cell fractions 2–5 from calvariae of Dmp1-
Topaz mice (Figure 1(a)). Topaz-positive cells exhibited a
stellate-shaped morphology (Figure 1(b)). We confirmed
that expression of osteocyte-specific genes, such as Dmp1
and SOST, was higher in Topaz-positive cells than in osteo-
blasts (Figure 1(c)).
3.2. TNF-α Enhances Sclerostin Expression of Osteocytes and
Sclerostin Promotes Osteoclastogenesis In Vitro. We per-
formed real-time RT-PCR to analyze SOST mRNA expres-
sion of osteocytes that were treated with TNF-α in vitro.
Compared with control (untreated) osteocytes, SOSTmRNA
expression increased in 1-day culture of TNF-α-treated oste-
ocytes; however, there was no significant difference in 3-day
culture (Figure 2(a)). Furthermore, to investigate the rela-
tionship between sclerostin and osteoclastogenesis, we cul-
tured osteocytes with rhSCL (0 ng/mL, 1 ng/mL, 10 ng/mL,
and 100 ng/mL) for 2 days. Compared with osteocytes treated
with 0ng/mL rhSCL, RANKL mRNA expression was signifi-
cantly increased in osteocytes treated with 100ng/mL rhSCL;
in contrast, OPG mRNA expression showed no significant
difference on the basis of rhSCL treatment (Figures 2(b)
and 2(c)). RANKL/OPG ratio was significantly increased in
osteocytes treated with 100ng/mL rhSCL (Figure 2(c)). The
effect on osteoclast formation was analyzed by coculture of
osteocytes and osteoclast precursors. The number of TRAP-
positive cells increased among osteocytes that were treated
with rhSCL (Figure 2(d)).
3.3. TNF-α Induced Osteoclastogenesis and Sclerostin
Expression of Osteocytes In Vivo. To investigate the effect of
TNF-α in vivo, we subcutaneously injected PBS or TNF-α
into mice cranial part for 5 days. The number of TRAP-
positive cells in the suture of histological sections from mice
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in the TNF-α-injected group was significantly increased,
compared with that of mice in the PBS-injected group
(Figure 3(a)). Immunohistochemical analysis showed that
the percentage of sclerostin-positive osteocytes was higher
in sections from mice in the TNF-α group than in sections
from mice in the PBS group (Figure 3(b)). Real-time RT-
PCR results also revealed that SOSTmRNA expression levels
were higher among mice in the TNF-α group than among
mice in the PBS group (Figure 3(c)).
3.4. TNF-α Affects Sclerostin Expression in Osteocytes during
OTM. As an OTM model, a Ni-Ti closed-coil spring was
fixed between the upper anterior alveolar bone and the
upper-left first molar to move the first molar in the mesial
direction in both WT and TNFRsKO mice (Figures 4(a)
and 4(b)). Sections underwent immunohistochemical stain-
ing, and sclerostin-positive osteocytes were evaluated under
an optical microscope. This analysis revealed that the per-
centage of sclerostin-positive osteocytes in TNFRsKO mice
was less than that of WT mice after 6 days of OTM, whereas
there was no significant difference between groups after 2
days of OTM (Figures 4(c) and 4(d)).
4. Discussion
In this study, we found that stimulation with TNF-α
increased sclerostin expression in primary osteocytes. In


















































































































Figure 1: Characteristics of isolated Topaz-positive cells. (a) Sorting of Topaz-positive cells with the FACSAria II Cell Sorter. (b) Morphology
of Topaz-positive cells. (c) Expression levels of DMP1 and SOST mRNA in the osteoblast-rich fraction (fraction 2) and in all Topaz-positive
cells (n = 4; ∗P < 0 05 and ∗∗P < 0 01).
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formation in vitro. Furthermore, stimulation with TNF-α
enhanced the expression of sclerostin in osteocytes in vivo.
Notably, we evaluated the effect of TNF-α on the expression
of sclerostin in osteocytes during OTM; we showed that
sclerostin was increased in WT mice but not in TNFRsKO
mice during OTM. Our findings suggest that TNF-α plays
an important role in increasing the expression of sclerostin
in osteocytes and enhancing osteoclast formation during
OTM. This experiment is the first to demonstrate an interac-
tion between TNF-α stimulation and sclerostin expression in
osteocytes during OTM.
Osteocytes are the most abundant cells in bone tissue, but
their role in bone remodeling has been unclear because they
are embedded in a mineralized matrix and are difficult to iso-
late. Notably, the murine long bone osteocyte Y4 (MLO-Y4)
cell line was generated to study osteocyte function [37].
While MLO-Y4 cells are osteocyte-like, they do not nec-



































































































































































































































Figure 2: Tumor necrosis factor alpha (TNF-α) enhanced sclerostin expression in primary osteocytes, and sclerostin enhanced
osteoclastogenesis in vitro. (a) Expression of SOST mRNA in osteocytes, analyzed by real-time reverse transcription polymerase
chain reaction (RT-PCR). Total RNA in osteocytes was isolated from osteocytes cultured with or without TNF-α for 1 or 3 days
(n = 4; ∗∗P < 0 01). (b) Expression of RANKL mRNA in osteocytes, analyzed by real-time RT-PCR. Total RNA from osteocytes was
isolated from osteocytes cultured with recombinant human sclerostin (rhSCL) (0 ng/mL, 1 ng/mL, 10 ng/mL, and 100 ng/mL) for 2 days
(n = 4; ∗P < 0 05). (c) Expression levels of RANKL and OPG mRNA, as well as RANKL/OPG ratio in osteocytes, analyzed by real-time RT-
PCR. Total RNA was isolated from osteocytes cultured with or without rhSCL (100 ng/mL) for 2 days (n = 4; ∗P < 0 05 and ∗∗P < 0 01).
(d) Microscopic photos and the numbers of tartrate-resistant acid phosphatase- (TRAP-) positive cells within a coculture of
osteocytes and osteoclast precursors, with or without rhSCL, in the presence of vitamin D3 and prostaglandin E2. Scale bars = 100 μm
(n = 4; ∗P < 0 05).
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Although there is an established method for isolation of pri-
mary osteocytes—the so-called “conventional method”—it
produces approximately 60% osteocytes [38]. Recently, a
new method for isolating primary osteocytes was established
using mice with osteocyte-specific expression of GFP [16];
this method enabled isolation of osteocytes with greater
purity than that demonstrated by the conventional method.
Therefore, we used this new method to isolate primary oste-
ocytes from DMP1-Topaz mice, which express the Topaz
variant of GFP under the direction of the mouse Dmp1 pro-
moter. In the conventional method, fraction 5 is considered
to be the osteocyte-rich fraction [38]. We evaluated the
ratio of Topaz-positive cells in fraction 5, and found that it
was <10%. In addition, we evaluated the characteristics of
Topaz-positive cells by assessment of the osteocyte markers
Dmp1 and SOST, and found high expression of osteocyte
markers. These results suggested that the use of Dmp1-
Topaz mice enables purification of more osteocytes than that
enabled by the conventional method. Therefore, the Topaz-
positive cells purified as osteocytes may closely represent
the properties of osteocytes.
A few studies have reported the effect of TNF-α on scler-
ostin expression in osteocytes; for example, an increased level
of TNF-α is associated with estrogen deficiency, which may
stimulate sclerostin expression in osteocytes [39]. TNF-α
has also been shown to upregulate sclerostin expression in
MLO-Y4 cells [27]. In addition, treatment with a TNF-α
antagonist could reduce sclerostin expression in osteocytes
in diabetic rats with periodontitis [28]. In the present study,
we cultured Topaz-positive cells as primary osteocytes,
with or without TNF-α. Notably, 1-day culture with TNF-α
increased sclerostin expression in primary osteocytes, com-
pared with control osteocytes; however, 3-day culture with
TNF-α did not increase sclerostin expression. Thus, we
concluded that stimulation with TNF-α increased scleros-
tin expression in primary osteocytes in the initial stage
of culture. Next, to analyze the effect of sclerostin on
RANKL-induced osteoclastogenesis in vitro, we cultured
primary osteocytes with various concentrations of sclerostin
(0 ng/mL, 1 ng/mL, 10 ng/mL, and 100ng/mL), and found a
significant increase in the expression of RANKL mRNA with
100 ng/mL sclerostin. In the present study, RANKL mRNA
expression was slightly increased with 10 ng/mL sclerostin,
but there was no significant difference between 0ng/mL
and 10ng/mL sclerostin. However, at 100 ng/mL sclerostin



















































































































Figure 3: TNF-α enhanced osteoclastogenesis and sclerostin expression in osteocytes in vivo. (a) Images: histological sections of calvariae
were obtained from wild-type mice after 5 days of daily supracalvarial administration of phosphate-buffered saline (PBS) or 3.0 μg/day
tumor necrosis factor alpha (TNF-α). Sections were stained with tartrate-resistant acid phosphatase (TRAP); cells stained red are regarded
as TRAP-positive. Scale bars = 100 μm. Graph: the numbers of TRAP-positive cells on the calvariae (n = 4; ∗∗P < 0 01). (b) Images:
sections were immunolocalized with antibodies specific for sclerostin, then counterstained with hematoxylin. Scale bars = 100μm. Graph:
the numbers of sclerostin-positive osteocytes on the calvariae (n = 4; ∗∗P < 0 01). (c) SOST mRNA levels in mouse calvariae detected using
real-time reverse transcription polymerase chain reaction.
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contrast to what was reported by Wijenayaka et al., where
RANKL mRNA expression was significantly increased with
10 ng/mL sclerostin when added to culture of osteocyte-like
cells compared to untreated control [26]. We can attribute
the difference in response strength to the method used in
obtaining osteocytes; while this study relied on primary
osteocytes obtained from DMP1-Topaz mice through cell
sorting, others used osteocytes differentiated from normal
human bone-derived cells (NHBC) [26]. Other factors that
can contribute to the variation in the strength of response
are different culture conditions and different sources from
which osteocytes were obtained. Moreover, the ratio of
RANKL/OPG significantly increased upon stimulation with
100 ng/mL sclerostin. Sclerostin has been reported to stimu-
late RANKL expression in MLO-Y4 cells [26, 31]. Our exper-
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Figure 4: Tumor necrosis factor alpha (TNF-α) affects sclerostin expression in osteocytes during orthodontic tooth movement (OTM). (a)
Intraoral photograph of the OTM appliance. (b) Schematic diagram of orthodontic tooth movement of the upper-left first molar to the
mesial side. The black arrow indicates the direction of orthodontic force. (c, d) Images: the percentage of sclerostin-positive osteocytes was
examined in the range of 400μm× 200μm from the mesial periodontal ligament on the compression side around 150μm from the
distobuccal root branch of the upper-left first molar after 2-day (c) or 6-day OTM (d). Arrowheads indicate the sclerostin-positive cells.
Black arrows indicate the direction of orthodontic force. M, mesial side; D, distal side; a, alveolar bone; p, periodontal ligament; r, root.
Scale bars = 100 μm. Graphs: corresponding percentages of sclerostin-positive osteocytes during OTM (n = 4; ∗∗P < 0 01).
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primary osteocytes and MLO-Y4 cells. Moreover, when pri-
mary osteocytes and osteoclast precursors were cocultured,
the number of TRAP-positive cells increased in the presence
of sclerostin. Finally, sclerostin reportedly promotes osteo-
clast formation via RANKL expression in MLO-Y4 cells
[26, 31]. Our results regarding primary cells in this study sup-
port the previous in vitro findings.
We previously reported that osteoclasts can be induced in
calvariae in the presence of TNF-α in vivo [10, 11]. In the
present study, we analyzed osteoclast formation and scleros-
tin expression in osteocytes by subcutaneous injection of
TNF-α into mice cranial part for 5 days. First, we confirmed
that stimulation with TNF-α induced osteoclast formation in
calvariae by using TRAP staining, as in our previous studies
[10, 11]. Next, we investigated the effect of TNF-α on scleros-
tin expression in osteocytes by using immunohistochemical
analysis. We found that the percentage of sclerostin-positive
osteocytes and the expression level of SOST mRNA both
increased in the TNF-α group. Thus, TNF-α may enhance
sclerostin expression in osteocytes in vivo.
The levels of TNF-α have been reported to increase in the
gingival sulcus in humans during OTM [40, 41]. We previ-
ously showed that OTM was mediated by TNF-α, in studies
of TNFRsKO mice [13, 15]. Here, we used TNFRsKO mice
to assess the role of TNF-α in the induction of sclerostin in
osteocytes during OTM. Orthodontic force was applied to
the upper-left first molar in the mesial direction for 2 or 6
days. The percentage of sclerostin-positive osteocytes in the
compression side was significantly reduced in TNFRsKO
mice in the 6-day OTM group. Several studies have shown
that high sclerostin expression is maintained for 5–7 days
after the initiation of tooth movement [31, 32]. Importantly,
our results indicated that TNF-α influenced sclerostin
expression in osteocytes on day 6 of OTM. Moreover, recent
investigation has shown that RANKL expression and osteo-
clast formation were decreased in SOST-deficient mice com-
pared to wild-type mice at the compression side during OTM
[31]. These results suggest that sclerostin affects osteoclasto-
genesis at the compression side during OTM.
5. Conclusions
We found that TNF-α enhanced the expression of sclerostin
in osteocytes, and that sclerostin-induced RANKL expression
in osteocytes enhanced osteoclastogenesis during OTM. In
conclusion, we have obtained evidence that TNF-α plays an
important role on sclerostin expression in osteocytes on the
compression side during OTM (Figure 5).
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The supplementary materials contain a figure with the
analysis of TRAP-positive cells. To investigate the expression
of calcitonin receptor (CTR) on TRAP-positive cells, TRAP
staining and immunohistochemical staining were performed
on the calvariae of C57BL/6J mice. CTR-positive cells were
identified in the same area as multinucleated TRAP-
positive cells in the serial section (Figure S1A). The number
of CTR-positive cells in the suture of histological sections
from mice in the TNF-α-injected group was significantly
increased compared to that of mice in the PBS-injected group
(Figure S1B). Similar results to TRAP staining (Figure 3(a))
were obtained with immunohistochemical staining of calci-







Figure 5: Schematic diagram explaining the role of tumor necrosis
factor alpha (TNF-α) in inducing sclerostin expression in osteocytes
on the compression side during orthodontic tooth movement
(OTM). TNF-α enhances sclerostin expression in osteocytes;
then, sclerostin increases the expression of receptor activator of
nuclear factor kappa-B ligand (RANKL) by osteocytes. Hence, we
concluded that osteoclast formation was enhanced by TNF-α
through increased sclerostin expression in osteocytes on the
compression side during OTM.
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